These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 17574073)

  • 21. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
    Lupe K; D'Souza DP; Kwon JS; Radwan JS; Harle IA; Hammond JA; Carey MS
    Gynecol Oncol; 2009 Jul; 114(1):94-8. PubMed ID: 19406459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix.
    Thigpen T; Vance RB; Khansur T
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):67-75. PubMed ID: 7481864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
    McMeekin DS; Walker JL; Hartenbach EM; Bookman MA; Koh WJ;
    Gynecol Oncol; 2009 Jan; 112(1):134-41. PubMed ID: 18962846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
    Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
    Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy.
    Kastritis E; Bamias A; Bozas G; Koutsoukou V; Voulgaris Z; Vlahos G; Rodolakis A; Gika D; Papadimitriou C; Dimopoulos MA
    Gynecol Oncol; 2007 Feb; 104(2):372-6. PubMed ID: 17030353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Aravantinos G; Fountzilas G; Bamias A; Grimani I; Rizos S; Kalofonos HP; Skarlos DV; Economopoulos T; Kosmidis PA; Stathopoulos GP; Briasoulis E; Pectasides D; Samantas E; Timotheadou E; Papadimitriou C; Papanikolaou A; Onyenadum A; Papakostas P; Bafaloukos D; Dimopoulos MA;
    Eur J Cancer; 2008 Oct; 44(15):2169-77. PubMed ID: 18691879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
    Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
    Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
    Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
    Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Combination chemotherapy with paclitaxel and carboplatin (TC therapy) for endometrial cancer].
    Misawa A; Nagao M; Kushimoto T; Yasuda M
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1901-5. PubMed ID: 19011339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy in endometrial cancer.
    Obel JC; Friberg G; Fleming GF
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):459-68. PubMed ID: 16981669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
    Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
    Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
    Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
    Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
    Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Sykiotis C; Papachristodoulou A; Tountas N; Panayiotides J; Economopoulos T
    Gynecol Oncol; 2008 Sep; 110(3):299-303. PubMed ID: 18602677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy for recurrent cervical cancer.
    Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
    Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.
    Mountzios G; Bamias A; Voulgaris Z; Rodolakis A; Vlahos G; Gourgoulis G; Papaiakovou EE; Giannopoulos A
    Gynecol Oncol; 2008 Jan; 108(1):130-5. PubMed ID: 17988722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
    Pignata S; Scambia G; Pisano C; Breda E; Di Maio M; Greggi S; Ferrandina G; Lorusso D; Zagonel V; Febbraro A; Riva N; De Rosa V; Gallo C; Perrone F;
    Br J Cancer; 2007 Jun; 96(11):1639-43. PubMed ID: 17486128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.